摘要
目的研究配对盒基因9(Pax9)在非小细胞肺癌(NSCLC)患者血清中的表达及临床意义。方法采用酶联免疫吸附法(ELISA)检测35例NSCLC患者血清中Pax9的浓度,以42例肺良性病变(慢性阻塞性肺疾病、肺炎)患者和30例健康者作为对照,并分析Pax9的表达与NSCLC患者临床病理特征及预后的关系。结果 NSCLC患者血清中Pax9的浓度[(144.6±87.4)ng/ml]明显高于肺良性病变患者[(94.8±44.4)ng/ml]和健康者[(103.3±58.3)ng/ml],差异有统计学意义(P<0.05)。Pax9的表达水平与患者性别、年龄、吸烟史及淋巴转移等临床病理特征无关(P>0.05),但与肿瘤病理分型、TNM分期显著相关(P<0.05)。另外,Kaplan-Meier分析显示,Pax9高表达组患者的生存时间明显低于低表达组患者的生存时间(P<0.05)。COX回归分析结果表明,肿瘤TNM分期、淋巴转移和Pax9表达对非小细胞肺癌患者预后具有显著意义(P<0.05)。结论 Pax9在肺癌的发生发展中起一定作用,检测其血清含量对NSCLC的诊断具有重要的临床意义,其在血清中的过高表达有可能作为肺癌不良预后的评估指标。
Objective To explore the Clinical significance of detection of serum levels of Pax9 in pa- tients with non-small cell lung cancer （NSCLC）. Methods Enzyme-linked immuno-sorbent assay （ELISA） was used to detect the protein concentration of serum Pax9 in 35 lung cancer patients （ experiment group）. The serum samples of 42 lung benign disease cases and 30 healthy cases were selected as control groups. And the re- lationship between Pax9 expression and clinicopathologic characteristics including prognosis of patients with NSCLC was analyzed. Results The serum level of Pax9 in patients with lung cancer was significantly higher than that in control cases（ P 〈 0. 05 ）. The gene expression was unrelated to clinical and pathologic data such as patients＇gender, age, smoking history and lymph nodes metastasis （ P 〉 0. 05 ）, but it was closely correlated to tumor pathological type and TNM stage （ P 〈 0. 05 ）. Moreover, univariate prognostic factor analyzed by Kaplan- Meier method indicated that the survival time of patients with the high serum level of Pax9 was shorter than that of patients with the low level（ P 〈 0.05 ）. The serum level of Pax9 ~TNM stage of NSCLC and tumor pathological type signally affected prognosis in COX regression model （ P 〈 0.05 ）. Conclusion Pax9 is involved in the de- velopment of lung cancer. The detection of the serum levels of Pax9 plays an important role in the lung cancer patients＇ diagnoses. Its too high expression in the serum may be a poor prognostic index in non-small cell lung cancer.
出处
《中国实用医药》
2013年第5期1-3,共3页
China Practical Medicine
基金
广东省科技计划项目(项目编号:2009B030801176)
